CRMD · CorMedix Inc.

Summary

CorMedix Inc. released an updated investor presentation (Exhibit 99.1) and reaffirmed full-year 2027 DefenCath sales guidance of $100 million to $140 million, correcting an inadvertent $100 million to $125 million statement from its March 5, 2026 earnings call. The presentation provides 2026 revenue guidance of $300–320 million and adjusted EBITDA guidance of $100–125 million.

Key takeaways

• Reaffirmed FY 2027 DefenCath sales guidance $100–140 million
• Corrected March 5, 2026 earnings call DefenCath guidance to $100–140 million from $100–125 million
• FY 2026 revenue guidance $300–320 million
• FY 2026 adjusted EBITDA guidance $100–125 million
• FY 2026 DefenCath sales guidance $150–170 million
• Q4 2025 DefenCath sales $91 million